What is P21-Adamantane 10MG

P21-Adamantane 10MG is a chemically modified derivative of the synthetic neurogenic peptide P21, studied in research for its highly enhanced blood-brain barrier permeability and prolonged neuroprotective effects. It is intended exclusively for research use.

Regarding its chemical identity, P21-Adamantane has a molecular formula of C34H49N5O5 and a molecular weight of 607.8 g/mol. Its reported canonical sequence is Ac-Pro-Gly-Pro-Ile-Glu (conjugated with Adamantane). A confirmed CAS number is not available in open primary reference sources and is therefore omitted.

Its synonyms include P21-Adamantane.

Product for research use.

Mechanism of action of P21-Adamantane

Like its parent peptide P21, P21-Adamantane binds to the CNTF receptor and inhibits the action of Leukemia Inhibitory Factor (LIF), powerfully stimulating neurogenesis in the dentate gyrus. The adamantane conjugation significantly enhances the molecule’s lipophilicity.

Pharmacokinetics and pharmacodynamics of P21-Adamantane

The addition of the bulky, highly lipophilic adamantane group dramatically alters its pharmacokinetics. It drastically increases the rate and volume at which the peptide crosses the blood-brain barrier and slows down enzymatic degradation, creating a highly systemic, long-acting nootropic profile.

Scientific evidence on P21-Adamantane

The available evidence on P21-Adamantane is preliminary and largely inconclusive, and should be interpreted with caution. The literature describes it as having been investigated for multiple indications in preclinical models.

While standard P21 is heavily studied, the adamantane-conjugated version is a highly experimental research chemical. Preclinical models hypothesize that it delivers vastly superior concentrations of the active peptide to target neural tissues compared to standard aqueous delivery.

P21-Adamantane applications in research

Ideal for (research context):
– In vitro and preclinical studies of its specific receptor pathways.
– Investigation of tissue repair, cell proliferation, and functional restoration in laboratory models.
– Comparative work with related peptides.

Not applicable for:
– clinical, diagnostic or therapeutic use.
– Any administration to humans or animals outside of an authorized research protocol.

Product for research use.

P21-Adamantane protocols in preclinical studies

The literature consulted does not include numerical doses from studies that can be cited for P21-Adamantane, so no trial schemes or quantities are specified.

The presentations of this product (10MG) refer only to the amount of lyophilized peptide per vial (or volume for liquids) and do not constitute a dosage recommendation. The design of any protocol, including concentrations and working volumes, is the responsibility of the researcher, based on their experimental objectives and the relevant primary literature.

Information provided exclusively for research purposes.

Reconstitution and manipulation of P21-Adamantane

As a general guideline for laboratory handling, lyophilized peptides such as P21-Adamantane are usually reconstituted with bacteriostatic water (sterile water with approximately 0.9% benzyl alcohol).

Add the solvent slowly down the side of the vial, letting it run over the lyophilized powder; avoid injecting the stream directly onto the powder.
Do not shake: gently rotate the vial until completely dissolved.
Adjust the solvent volume according to the desired working concentration, considering the 10MG contents of the vial.

These guidelines are for general technique and do not replace the internal procedures of each laboratory.

P21-Adamantane Stability and Storage

As a standard laboratory handling procedure for peptides:

Freeze-dried (unreconstituted): This is the most stable form. It is best preserved by freezing and protecting it from moisture and light for long-term storage.
Reconstituted: once in solution, the peptide is less stable and must be kept refrigerated, being used within a short period; for extended storage, freezing in aliquots is usually preferred.
Avoid repeated freeze-thaw cycles, as they can degrade the peptide.

Given that the molecule is characterized by rapid enzymatic degradation in biological media, careful cold chain management is especially relevant.

Documented P21-Adamantane security profile

The documented safety information in open sources for P21-Adamantane is limited and should be interpreted with caution, also considering that it is research material and not for clinical use.

The adamantane group is used in several approved neurological drugs (like memantine and amantadine). However, conjugating it to a potent neurogenic peptide creates theoretical risks of overstimulating neurogenesis or accumulation in lipid-rich neural tissues, which remains unverified.

Formal contraindications and adverse event rates are not available in the consulted literature, so no figures are reported.

P21-Adamantane in a comparative context

Compared to standard P21, the adamantane version is significantly more bioavailable and requires less frequent dosing. It shares structural and conceptual similarities with other adamantane-based drugs like Bromantane, though its mechanism is strictly neurotrophic rather than dopaminergic.

History and development of P21-Adamantane

Developed by independent researchers looking to maximize the neurological impact of P21. Adamantane conjugation is a standard biochemical technique to turn hydrophilic peptides into highly penetrative, stable neurological agents.